Eugia Pharma receives USFDA Approval for Vasopressin Injection USP

Aurobindo Pharma Limited has announced that its wholly owned subsidiary company, Eugia Pharma Specialties Limited, has received a final approval from the US Food & Drug Administration (USFDA) to manufacture and market Vasopressin Injection USP, 20 Units/mL Multiple-Dose Vials. Vasopressin Injection USP, 20 Units/mL Multiple-Dose Vials, to be bioequivalent and therapeutically equivalent to the reference listed drug (RLD), Vasostrict Injection, 20 units/mL of Par Sterile Products, LLC (Par). The product is being launched Immediately. The approved product has an estimated market size of around US$ 606 million for the twelve months ending June 2022, according to IQVIA.

This is the 146th ANDA (including 10 tentative approvals received) out of Eugia Pharma Speciality Group (EPSG) facilities, manufacturing both oral and sterile specialty products.

Vasopressin Injection USP is indicated for the treatment of Cardiovascular agent: vasoconstrictor

- Indicated to increase blood pressure in adults with vasodilatory shock (e.g., post-cardiotomy or sepsis) who remain hypotensive despite fluids and catecholamines.

Shares of Aurobindo Pharma Limited was last trading in BSE at Rs. 593.30 as compared to the previous close of Rs. 575.45. The total number of shares traded during the day was 214340 in over 5711 trades.

The stock hit an intraday high of Rs. 603.80 and intraday low of 569.50. The net turnover during the day was Rs. 125706501.00.

Source : Equity Bulls

Keywords

AurobindoPharma INE406A01037 EugiaPharmaSpecialties FinalApproval USFDA VasopressinInjection